What this is
- This study compares the effectiveness of tirzepatide and semaglutide for managing obesity in adults without diabetes.
- Using a large electronic health record database, it evaluates real-world weight reduction and cardiometabolic outcomes over six months.
- Findings show that tirzepatide leads to greater weight loss and improved health markers compared to semaglutide.
Essence
- Tirzepatide treatment resulted in a greater mean percentage weight reduction of −11.15% compared to −8.83% for semaglutide at six months. Additionally, tirzepatide led to higher rates of achieving weight reduction targets and better cardiometabolic outcomes.
Key takeaways
- Tirzepatide produced a greater mean percentage weight reduction of −11.15% compared to −8.83% for semaglutide, with an adjusted difference of −2.32 percentage points. This indicates that tirzepatide is more effective for weight loss in clinical settings.
- Higher proportions of patients treated with tirzepatide achieved significant weight reduction targets: 85.7% reached ≥5%, 59.0% reached ≥10%, 31.2% reached ≥15%, and 11.3% reached ≥20%, compared to lower rates for semaglutide.
- Tirzepatide also resulted in greater improvements in cardiometabolic parameters, including reductions in blood pressure and HbA1c levels, suggesting additional health benefits beyond weight loss.
Caveats
- The study's observational nature may introduce residual confounding despite extensive adjustments. Causal relationships cannot be firmly established.
- The analysis was limited to a 6-month follow-up, which may not capture long-term treatment effects that could extend beyond this period.
- Missing clinical data may lead to selection bias, as patients with complete data may differ systematically from those without.
Simplified
Introduction
Obesity is a chronic, progressive, relapsing disease that affects over 40% of adults in the US [1] and is associated with increased risk of morbidity, disability, mortality, and reduced quality of life [2–4]. Obesity management medications (OMMs) play an increasingly important role alongside lifestyle interventions and metabolic bariatric surgery to treat the disease of obesity [5, 6]. In particular, GLP-1 receptor agonists such as semaglutide and the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide have demonstrated substantial efficacy for weight reduction in individuals with obesity. The SURMOUNT-5 trial, a phase 3b, head-to-head, open-label, active comparator study of 751 adults with obesity, without diabetes, demonstrated the superior efficacy of tirzepatide vs. semaglutide in percentage weight change and weight reduction targets of ≥ 10%, ≥ 15%, ≥ 20%, and ≥ 25% at 72 weeks [7]. Additionally, tirzepatide demonstrated significantly greater improvements than semaglutide at 72 weeks in cardiometabolic risk parameters, including systolic and diastolic blood pressure (SBP, DBP), haemoglobin HbA1c, fasting insulin, triglycerides, and high-density lipoprotein (HDL) cholesterol.
Despite the growing use of these medications for obesity management, to our knowledge, no real-world evaluation has compared the effectiveness of tirzepatide and semaglutide in populations with the disease of obesity, without diabetes. Existing observational studies comparing weight reduction with these two treatments were conducted in patients with and without type 2 diabetes before FDA approval of tirzepatide for obesity management [8–15].
This study aimed to address this knowledge gap by assessing the comparative effectiveness of these medications approved for obesity management among US adults with the disease of obesity, without diabetes in routine care settings.
Methods
Data sources
The study was conducted using the Truveta electronic health record (EHR) database, which aggregates de-identified patient data from 30 health systems across all 50 US states. The data encompass a wide range of care settings and include patient demographics, diagnoses, procedures, medications (ordered, administered, and dispensed), laboratory and vital sign measurements, and social determinants of health (e.g., education and income, when available). The dataset used in this study reflected records available as of December 13, 2024. Dates in the Truveta database are shifted by up to 30 days to protect patient privacy, and all data are de-identified in accordance with the Health Insurance Portability and Accountability Act (HIPAA) Expert Determination standard. Because this was a retrospective study using de-identified secondary data, no institutional review board approval or informed consent was required.
Study population
The study population included adults (aged ≥ 18 years) with body mass index (BMI) ≥ 27 kg/m² with ≥ 1 obesity-related complication or BMI ≥ 30 kg/m², who initiated tirzepatide (Zepbound®) or semaglutide (Wegovy®) for obesity management between December 1, 2023, and June 30, 2024. The first recorded dispensing of either of these medications in the database was deemed the index date. Obesity-related complications were identified within the 12-month period before index date (“baseline”) (Online Resource, p. 14). Patients were further required to have ≥ 1 record of clinical activity during the 6 months after index (“follow-up”) and in each consecutive 6-month period of baseline, and ≥ 1 record of weight and/or BMI within 60 days prior to index and 30 days before or after the end of the 6-month follow-up period. In addition, patients were required to be adherent to the index treatment, with a proportion of days covered ≥ 80% during the follow-up period (on-treatment cohort). Patients with GLP-1 receptor agonists or dual GIP and GLP-1 receptor agonist use during the 12-month baseline period were excluded, as were those with diabetes, prior metabolic bariatric procedures, or conditions associated with unintentional weight change. See Online Resource p. 3 for additional details regarding the selection criteria and associated definitions.
Outcomes
The primary outcome was percentage change in body weight (i.e., weight) from index to 6 months.
Additional weight-related outcomes included the percentage of patients achieving ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% weight reduction targets, absolute weight change from index (kg), absolute change in BMI (kg/m²), and BMI class shift, defined as a transition from one BMI category to a lower one over the 6-month follow-up.
Cardiometabolic risk parameters included changes in SBP, DBP, HbA1c, and lipid parameters (i.e., total cholesterol, HDL cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides). For each measure, absolute and percentage change from index to 6 months were reported. Analyses were restricted to patients with non-missing values at both timepoints. Definitions for study outcomes and derived measures are detailed in the Online Resource (p. 256).
Statistical analyses
The primary analysis estimand was the average treatment effect on the treated (ATT), estimated using a propensity score (PS) weighting approach in the on-treatment cohort. Under the primary analysis method, the treatment models for generating propensity scores were generalized boosted models [16] with the treatment indicator as a binary outcome and baseline covariates including sociodemographic variables: age (continuous), sex, race, ethnicity, geographic region, education level, individual and household income; anthropometric and clinical characteristics: index weight, BMI, BMI class (overweight, obesity class I–III), and comorbidities (see Online Resource for full list and definitions); healthcare system interactions: number of medical encounters, prescriptions, and laboratory assessments; and use of non-incretin OMMs (i.e., phentermine, phentermine/topiramate, bupropion/naltrexone). ATT weights were set to 1 for tirzepatide-treated patients and set to PS/(1–PS) for semaglutide-treated patients. Covariate balance was assessed using absolute standardized mean differences (ASMDs), with values < 0.1 considered acceptable, and variance ratios, with values between 0.5 and 2.0 considered acceptable.
Weighted treatment effect estimates were generated using generalized linear models (GLMs) with robust standard errors. For continuous outcomes (i.e., percent and absolute change in weight, BMI, and change in cardiometabolic parameters), results were reported as adjusted least squares mean differences (LSMDs) with 95% confidence intervals (CIs). For binary outcomes (i.e., ≥ 5%, ≥ 10%, ≥ 15%, or ≥ 20% weight reduction; BMI class shift), results were reported as adjusted odds ratios (aORs) with 95% CIs calculated using observed margins. In addition to PS weighting, outcome models were adjusted further using the following prespecified baseline covariates to help mitigate residual confounding: age, sex, race, ethnicity, value of the outcome, number of obesity-related comorbidities, and baseline use of non-incretin OMMs.
The main analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and R Version 4.2.3 (R Foundation for Statistical Computing, Vienna, Austria). A list of R packages used for the analyses is provided in the Online Resource (p. 6).
Handling of missing data
For all outcomes, patients were required to have non-missing values at both baseline and 6-month follow-up to be included in the analysis for that outcome. For missing weight, values were derived using BMI and height, as available. For missing BMI, values were derived using height and weight, as available. No imputation was applied for other outcome measures. When multiple values were available within the allowable baseline or follow-up windows, the closest valid value to the target timepoint was used, and implausible values were excluded based on predefined rules (Online Resource, p. 4).
For cardiometabolic parameters, all analyses were conducted within subsets with non-missing outcome data, with PS weights re-estimated in those subsets.
Sensitivity analyses
Prespecified sensitivity analyses were conducted to evaluate the robustness of the primary outcome analyses, i.e., percentage weight change and other select additional outcomes and their sensitivity to alternative methodological assumptions and potential sources of bias.
The primary analysis was repeated for a broader modified intention-to-treat (mITT) cohort, which included patients regardless of adherence or switching status but required all other selection criteria applied to the primary cohort, including having non-missing baseline and 6-month outcome data. This analysis estimated the treatment effect of therapy initiation, regardless of subsequent treatment choices.
A Frequentist Model Averaging (FMA) analysis [17] was conducted to evaluate the robustness of the primary analysis method. FMA incorporated 11 alternative analytic strategies combining different treatment models (e.g., Least Absolute Shrinkage and Selection Operator [LASSO] regression, gradient boosting) and outcome models (e.g., GLMs, LASSO regression) to derive final estimates as weighted averages across models (details in Online Resource, p. 10).
An analysis based on principal stratification approach [18] was conducted in the mITT cohort to estimate the effect of tirzepatide vs. semaglutide in a hypothetical population of patients who would be adherent to tirzepatide if assigned to it (irrespective of actual treatment assignment), enabling a comparison that isolates the treatment effect in the subgroup most likely to adhere to tirzepatide therapy (details in Online Resource, p. 12).
Robustness of the treatment effect estimates was also assessed using the E-value [19], which quantifies the minimum strength of association on the risk ratio (RR) scale that an unmeasured confounder would need to have with both the treatment and the outcome to fully explain away the treatment effect, accounting for all observed confounders (details in Online Resource, p. 13).
Role of the funding source
This study was funded by Eli Lilly and Company, which conceived the study idea, provided access to the data, and led the overall study design and interpretation. Primary and secondary analyses were conducted by Analysis Group, Inc. under contract with Eli Lilly and Company. Additional sensitivity analyses including FMA were conducted independently by Eli Lilly and Company.
Authors affiliated with Eli Lilly and Company, Analysis Group, Inc., and University College Dublin contributed to study design, statistical analysis, data interpretation, and drafting and critical revision of the manuscript. All authors had full access to the final study outputs and take responsibility for the decision to submit the manuscript for publication.
Results
Baseline characteristics
A total of 2,396 patients met criteria for the on-treatment cohort, including 1,003 patients treated with tirzepatide and 1,393 treated with semaglutide (Fig. 1).
The baseline demographic and clinical characteristics of the two treatment groups before and after PS weighting are presented in Table 1. Briefly, patients in the tirzepatide and semaglutide groups had a mean age of 48.4 and 49.1 years, respectively. More patients in the semaglutide group were female (73.2%) and Black (18.0%) compared with those treated with tirzepatide (69.9% female; 11.5% Black, ASMD = 0.072 and 0.186, respectively). Conversely, more patients in the tirzepatide group had a college degree (60.8%) compared with semaglutide (57.9%, ASMD = 0.059). At baseline, the average weight and BMI in the tirzepatide group were approximately 104.0 kg and 38.3 kg/m2 vs. 104.6 kg and 38.4 kg/m2 in the semaglutide group, respectively. However, slightly more patients in the semaglutide group had Class III obesity (BMI ≥ 40 kg/m2) compared with the tirzepatide group (35.7% vs. 32.9%, ASMD = 0.059). The rates of various obesity-related complications and other comorbidities assessed in the study were generally similar between the two groups (ASMD < 0.1).
Patients initiating tirzepatide were most frequently started on the lowest available dose (91.0% at 2.5 mg) (Fig. 2) [20, 21]. In comparison, 79.9% of semaglutide initiators started on the lowest dose of 0.25 mg. By month 6, fewer tirzepatide patients received the highest available doses (≥ 10 mg) compared to semaglutide (≥ 1.7 mg) (42.4% vs. 67.7%).
The ASMDs for all characteristics were less than 0.1 (Table 1) and variance ratios for all continuous covariates were close to 1.0 after PS weighting (Online Resource p. 257), suggesting good balance was achieved between the two treatment groups. The PS distribution before and after adjustment and the PS weights distribution are presented in the Online Resource (p. 271–272).
Cohort construction flowchart. BMI = body mass index; FDA = Food & Drug Administration; GIP = glucose-dependent insulinotropic peptide; GLP-1 = glucagon-like peptide 1; OMM = obesity management medication; RA = receptor agonist
Dosage for the index fill and last observed fill in the 6-month follow-up period in patients treated with tirzepatide and semaglutide in the on-treatment cohort, after PS weighting. ESS = effective sample size; PS = propensity score; SEMA = semaglutide; TZP = tirzepatide. Percentages do not sum to 100% due to small percentages with unknown dose strength values
| Characteristic | Tirzepatide= 1,003N | Before PS Weighting | After PS Weighting | ||
|---|---|---|---|---|---|
| Semaglutide= 1,393N | ASMD | Semaglutide= 1,393ESS = 1,202Na | ASMD | ||
| ,Age on index (years)mean (SD) | 48.4 (12.2) | 49.1 (11.9) | 0.064 | 48.3 (11.8) | 0.004 |
| Female | 69.9% | 73.2% | 0.072 | 71.1% | 0.027 |
| Race | |||||
| White | 75.2% | 68.6% | 0.146 | 73.9% | 0.029 |
| Black | 11.5% | 18.0% | 0.186 | 12.4% | 0.028 |
| Asian | 1.6% | 1.4% | 0.013 | 1.6% | 0.002 |
| American Indian or Alaska Native | 4.9% | 0.6% | 0.02 | 5.5% | 0.014 |
| Native Hawaiian or Other Pacific Islander | 6.9% | 0.3% | 0.043 | 6.7% | 0.049 |
| Other | 75.2% | 4.7% | 0.018 | 73.9% | 0.014 |
| Unknown | 11.5% | 6.3% | 0.023 | 12.4% | 0.009 |
| Ethnicity | |||||
| Not Hispanic or Latino | 82.5% | 81.8% | 0.018 | 82.4% | 0.025 |
| Hispanic or Latino | 11.3% | 12.3% | 0.034 | 12.1% | 0.027 |
| Unknown | 6.3% | 5.9% | 0.017 | 5.5% | 0.003 |
| US Census region | |||||
| South | 42.3% | 43.6% | 0.026 | 44.9% | 0.027 |
| West | 14.7% | 15.9% | 0.034 | 14.4% | 0.035 |
| Midwest | 13.4% | 12.2% | 0.035 | 12.1% | 0.037 |
| Northeast | 2.3% | 0.6% | 0.137 | 1.1% | 0.088 |
| Unknown | 27.4% | 27.7% | 0.007 | 27.4% | 0.004 |
| Education level | |||||
| College degree | 60.8% | 57.9% | 0.059 | 59.6% | 0.006 |
| No college | 22.7% | 27.6% | 0.112 | 24.7% | 0.01 |
| Some college | 0.0% | 0.0% | 0 | 0.0% | 0 |
| Unknown | 16.5% | 14.5% | 0.054 | 15.7% | 0.02 |
| Income level (USD) | |||||
| 0–25k | 0.5% | 0.6% | 0.02 | 0.5% | 0.009 |
| 25–50k | 15.2% | 19.3% | 0.11 | 16.3% | 0.024 |
| 50–100k | 36.8% | 31.4% | 0.113 | 35.3% | 0.034 |
| 100–150k | 10.1% | 9.8% | 0.01 | 9.3% | 0.013 |
| ≥150k | 0.5% | 0.3% | 0.034 | 0.3% | 0.023 |
| Unknown | 37.0% | 38.5% | 0.032 | 38.2% | 0.028 |
| Household income level (USD) | |||||
| 0–25k | 0.1% | 0.6% | 0.09 | 0.3% | 0.041 |
| 25–50k | 6.4% | 10.0% | 0.132 | 6.9% | 0.02 |
| 50–100k | 47.9% | 43.1% | 0.095 | 47.1% | 0.015 |
| 100–150k | 4.8% | 5.0% | 0.008 | 4.9% | 0.006 |
| ≥150k | 0.0% | 0.0% | 0 | 0.0% | 0 |
| Unknown | 40.9% | 41.3% | 0.008 | 40.8% | 0.001 |
| ,Weight (kg)mean (SD) | 104.0 (26.0) | 104.0 (26.0) | 0.021 | 104.4 (24.8) | 0.013 |
| ,BMI (kg/m)mean (SD)2 | 38.3 (7.2) | 38.3 (7.2) | 0.018 | 38.1 (6.8) | 0.024 |
| BMI class | |||||
| Class 3 obesity (BMI ≥ 40 kg/m)2 | 32.9% | 35.7% | 0.059 | 33.0% | 0.001 |
| Class 2 obesity (BMI ≥ 35 and < 40 kg/m)2 | 28.0% | 27.7% | 0.007 | 28.6% | 0.014 |
| Class 1 obesity (BMI ≥ 30 and < 35 kg/m)2 | 33.0% | 29.8% | 0.069 | 32.5% | 0.01 |
| Overweight (BMI ≥ 25 and < 30 kg/m)2 | 6.1% | 6.8% | 0.03 | 5.9% | 0.009 |
| Number of obesity-related complications | 1.5 (1.3) | 1.6 (1.3) | 0.064 | 1.5 (1.3) | 0.004 |
| Dyslipidaemia | 48.3% | 47.2% | 0.022 | 46.7% | 0.03 |
| Hypertension | 44.1% | 47.5% | 0.069 | 45.6% | 0.03 |
| Prediabetes | 16.3% | 19.7% | 0.091 | 17.0% | 0.019 |
| Obstructive sleep apnea | 16.8% | 17.7% | 0.023 | 16.9% | 0 |
| Osteoarthritis knee and/or hip | 8.2% | 9.5% | 0.048 | 8.5% | 0.012 |
| Atherosclerotic cardiovascular disease | 8.2% | 8.9% | 0.026 | 8.2% | 0 |
| Metabolic dysfunction-associated steatotic liver disease/steatohepatitis | 5.9% | 6.2% | 0.012 | 6.3% | 0.016 |
| Metabolic syndrome | 2.5% | 1.8% | 0.048 | 1.9% | 0.043 |
| Chronic heart failure - HFpEF | 0.5% | 0.3% | 0.034 | 0.2% | 0.053 |
| ,Number of other comorbiditiesmean (SD) | 2.2 (1.7) | 2.3 (1.8) | 0.052 | 2.1 (1.7) | 0.03 |
| Use of any non-incretin OMM | 11.0% | 12.3% | 0.041 | 11.5% | 0.016 |
Weight reduction outcomes
In the primary on-treatment analysis, tirzepatide-treated patients had an adjusted percentage weight change of −11.15% (95% CI −11.82 to −10.48) compared to −8.83% (95% CI −9.33 to −8.33) among the semaglutide-treated patients, with an adjusted mean difference of −2.32% points (95% CI −3.17 to −1.48) in favour of tirzepatide (Fig. 3, Panel A). At 6 months, 85.7% of tirzepatide-treated patients achieved ≥ 5% weight reduction, compared to 75.2% in the semaglutide-treated group (aOR 2.03 [95% CI 1.63 to 2.54]). Greater percentages of tirzepatide-treated vs. semaglutide-treated patients also achieved ≥ 10% weight reduction (59.0% vs. 38.0%, aOR 2.46 [2.06 to 2.93]), ≥ 15% weight reduction (31.2% vs. 14.0%, aOR 2.88 [2.32 to 3.57]), and ≥ 20% weight reduction (11.3% vs. 3.8%, aOR 3.23 [2.29 to 4.55]) (all p < 0.0001) (Fig. 3, Panel B).
The 6-month adjusted mean absolute change in weight was −12.36 kg (95% CI −12.90 to −11.82) among tirzepatide-treated patients and −9.45 kg (95% CI −9.89 to −9.01) among semaglutide-treated patients, yielding an adjusted mean difference of −2.91 kg (95% CI −3.61 to −2.22; p < 0.0001) in favour of tirzepatide (Table 2).
In parallel with weight changes, the 6-month adjusted mean absolute change in BMI was −5.12 kg/m² (95% CI −5.30 to −4.94) in tirzepatide-treated patients vs. −3.86 kg/m² (95% CI −4.04 to −3.69) in semaglutide-treated patients, yielding an adjusted difference of −1.25 kg/m² (95% CI −1.50 to −1.00; p < 0.0001) in favour of tirzepatide (Table 2). BMI class shift also favoured tirzepatide. A significantly higher percentage of patients receiving tirzepatide achieved ≥ 1 reduction in BMI category compared with those receiving semaglutide (68.8% vs. 54.8%; aOR: 1.92; 95% CI 1.59 to 2.32; see Online Resource p. 267).
Adjusted 6-month mean percentage weight change in patients treated with tirzepatide and semaglutide and adjusted difference, primary analysis method (); adjusted odds ratios for categorical 6-month weight reductions, primary analysis method (); adjusted mean percentage weight change, sensitivity analyses (). ∆ = change; aOR = adjusted odds ratio; ATT = average effect of treatment on the treated; CI = confidence interval; FMA = frequentist model averaging; LCL = lower confidence limit; mITT = modified intention-to-treat; PS = propensity score; SEMA = semaglutide; TZP = tirzepatide; UCL = upper confidence limit. Estimates in () and () were adjusted using ATT PS weights and multivariate regression modeling (primary analysis method). Estimates in () were obtained using each sensitivity analysis as indicated a b c a b c
| N | Baseline Mean | 6-Month Mean | Adjusted Mean Change | Adjusted Mean Difference[95% CI]a | -valueP | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Outcome | TZP | SEMA | TZP | SEMA | TZP | SEMA | TZP | SEMA | ||
| Weight, kg | 1,003 | 1,393 | 103.6 | 103.9 | 93.5 | 96.4 | −12.36 | −9.45 | −2.91,[−3.61−2.22] | < 0.0001* |
| BMI, kg/m2 | 1,003 | 1,393 | 38.3 | 38.1 | 33.2 | 34.3 | −5.12 | −3.86 | −1.25,[−1.501.00] | < 0.0001* |
| Systolic blood pressure, mmHg | 798 | 1,173 | 127.7 | 127.4 | 120.2 | 121.8 | −7.32 | −5.90 | −1.42,[−2.50−0.35] | 0.0097* |
| Diastolic blood pressure, mmHg | 800 | 1,178 | 80 | 79.7 | 76.4 | 77.5 | −3.51 | −1.99 | −1.52,[−2.29−0.75] | 0.0001* |
| HbA1c, percent | 69 | 106 | 5.7 | 5.7 | 5.2 | 5.4 | −0.52 | −0.37 | −0.15,[−0.24−0.05] | 0.0042* |
| Total cholesterol, mg/dL | 62 | 110 | 191 | 192.3 | 172.7 | 171.8 | −19.39 | −22.49 | 3.1 [−6.26, 12.46] | 0.5134 |
| LDL cholesterol, mg/dL | 27 | 47 | 124.6 | 130.9 | 108.9 | 111.7 | −17.52 | −19.14 | 1.62 [−8.96, 12.19] | 0.7609 |
| HDL cholesterol, mg/dL | 69 | 119 | 50.9 | 50.4 | 51.5 | 49.6 | 0.35 | −1.86 | 2.21 [−1.08, 5.49] | 0.1861 |
| Triglycerides, mg/dL | 78 | 137 | 153 | 147 | 113.7 | 118.1 | −37.17 | −31.67 | −5.50 [−19.90, 8.90] | 0.4522 |
Cardiometabolic risk parameters
Cardiometabolic risk parameters were assessed in on-treatment subsets with non-missing values at baseline and 6-month follow-up, ranging from 74 patients (LDL cholesterol) to 1,978 patients (DBP) (Table 2). Tirzepatide was associated with greater improvements in mean DBP (−3.51 mmHg vs. −1.99 mmHg; adjusted difference −1.52, 95% CI −2.29 to −0.75), mean SBP (−7.32 mmHg vs. −5.90 mmHg; difference −1.42, 95% CI −2.50 to −0.35), and mean HbA1c (−0.52% vs. −0.37%; difference −0.15, 95% CI −0.24 to −0.05) compared to semaglutide. These findings were directionally consistent across both percentage and absolute change analyses. Adjusted percentage changes in lipid parameters were not different between treatment groups. Full results are reported in the Online Resource (p. 266).
Sensitivity analyses
In the mITT cohort, tirzepatide was associated with significantly greater weight reduction than semaglutide (Fig. 3, Panel C). The adjusted mean percentage weight change was −9.19% (95% CI −9.68 to −8.70) for tirzepatide vs. −6.94% (95% CI −7.33 to −6.55) for semaglutide, with an adjusted difference of − 2.25% points (95% CI −2.88 to −1.63).
Results from the sensitivity analyses using FMA and principal stratification in the on-treatment cohort were consistent with the primary analysis and are reported in Fig. 3 (Panel C) as well as in the Online Resource (p. 275). Across analytic strategies, the estimated differences in weight change between cohorts ranged from −2.53 (95% CI −3.18 to −1.93) to −4.09 (95% CI −4.88 to − 3.30) percentage points in favour of tirzepatide. The E-value analysis indicated that an unmeasured confounder would need an extremely strong association (RR > 16) with treatment selection and percentage weight change to nullify the observed advantage of tirzepatide over semaglutide (Online Resource p. 280). Even to reduce treatment effect to the lower confidence bound, a substantial confounder (RR > 7) would be required.
Achievement of categorical weight reduction targets in the mITT cohort similarly favoured tirzepatide. The adjusted percentage of patients achieving ≥ 5% weight reduction was 74.4% with tirzepatide and 61.7% with semaglutide (aOR: 1.80; 95% CI 1.57 to 2.07). The adjusted rates were 45.5% and 29.4%, respectively (aOR: 2.01; 95% CI 1.76 to 2.29) for ≥ 10% weight reduction; 23.3% vs. 10.8%, respectively (aOR: 2.51; 95% CI: 2.11 to 3.00) for ≥ 15% weight reduction; and 9.4% vs. 3.0%, respectively (aOR: 3.38; 95% CI 2.51 to 4.54) for ≥ 20% weight reduction (Online Resource p. 269–270).
Discussion
In this large real-world comparative effectiveness study of adults without diabetes initiating pharmacotherapy for obesity management, tirzepatide was associated with greater reductions in weight and BMI, and a higher likelihood of achieving weight reduction targets of ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% at 6 months compared with semaglutide. Although the adjusted mean difference in weight reduction between treatments at 6 months was moderate in absolute terms, categorical outcomes reflect its strong clinical importance: for example, approximately twice as many tirzepatide-treated patients achieved ≥ 15% weight reduction compared with semaglutide-treated patients (31% vs. 14%). These differences were robust across multiple population specifications and analytic approaches. Tirzepatide was also associated with greater improvements in mean systolic and diastolic blood pressure and HbA1c compared to semaglutide, though differences in lipid parameters were similar.
These real-world findings complement and extend results from randomized controlled trials of tirzepatide and semaglutide for obesity management. In the SURMOUNT-1 trial, patients without diabetes treated with tirzepatide 15 mg achieved a mean weight reduction of 16.0% at 72 weeks [22], while semaglutide 2.4 mg in the STEP-1 trial yielded a 14.9% reduction over a similar period (treatment regimen estimand) [23]. Recently reported results using the efficacy estimand from SURMOUNT-5, a direct comparison of tirzepatide and semaglutide in adults with obesity, found a 21.6% weight reduction with tirzepatide vs. 15.4% with semaglutide at 72 weeks, confirming the superior efficacy of tirzepatide in a randomized setting [7]. In SURMOUNT-5, at 24 weeks, tirzepatide 10 or 15 mg led to an estimated mean percentage weight reduction of 14.4% (95% CI −15.0% to −13.8%) compared with 10.8% (95% CI –11.4% to −10.2%) for semaglutide 1.7 or 2.4 mg (efficacy estimand). The current study provides support for these findings in a real-world clinical setting, demonstrating that tirzepatide was associated with greater weight reduction than semaglutide in a patient population treated for obesity management—rather than for glycaemic control.
Importantly, the magnitude of weight reduction observed in the current 6-month analysis (−11.15% with tirzepatide vs. −8.83% with semaglutide in the on-treatment cohort) aligns closely with interim timepoints in these pivotal trials and supports the early emergence and clinical meaningfulness of the comparative advantage of tirzepatide over semaglutide. The achievement of weight-reduction targets was also more common with tirzepatide than semaglutide, further aligning with SURMOUNT-5 findings. Moreover, despite more semaglutide-treated patients starting at doses higher than the minimal dose and reaching the higher approved maintenance doses (i.e., ≥ 10 mg for tirzepatide and ≥ 1.7 mg for semaglutide) during follow-up, weight reduction remained greater in the tirzepatide group. Given identical follow-up duration and labeled 4-week titration permitting escalation to ≥ 10 mg (tirzepatide) and ≥ 1.7 mg (semaglutide) by week 16, this difference likely reflects clinical titration patterns and differences in clinical effectiveness between the two treatments rather than limited time to escalate. Taken together, our findings support the external validity of trial-based evidence and highlight the real-world effectiveness of tirzepatide in US clinical practice.
The results of this study are also consistent with previous real-world studies that compared the effectiveness of tirzepatide vs. semaglutide for weight reduction, using data from time periods prior to the approval of tirzepatide for obesity management. In particular, using the same data source but from May 2022 to September 2023 instead, Rodriguez et al. (2024) found that among the subpopulation without type 2 diabetes, patients treated with tirzepatide had greater mean percentage weight reduction at 6 months compared to similar patients treated with semaglutide, with a difference of approximately 4.5% points [8]. Trinh et al. (2025) found that patients without diabetes lost an average of 7.0% of their weight over 6 months if treated with tirzepatide compared to 3.4% if treated with semaglutide, but the study did not analyse dose or titration schedules [9]. Several observational studies have reported greater 12-month weight loss with tirzepatide than semaglutide approved for the treatment of type 2 diabetes, but differences in follow-up duration, dosing, and adherence limit comparability with shorter-term outcomes [12, 13]. Other retrospective cohort studies found similar results on weight reduction in populations with conditions other than obesity [10, 11, 14, 15].
This study has several strengths. First, we leveraged a large, geographically diverse real-world database spanning multiple US health systems, enabling the evaluation of treatment effectiveness in a clinically relevant population of adults treated specifically for obesity management—rather than glycaemic control. The analysis employed a robust causal inference framework, multiple analytic strategies under an FMA framework, and extensive sensitivity analyses such as principal stratification and E-value estimation. These methods collectively enhance the internal validity of the findings, attempt to mitigate observed confounding, as well as help understand the impact of confounding due to unmeasured factors. The inclusion of both continuous and categorical weight reduction measures, BMI measures, and cardiometabolic parameters provides a comprehensive overview of comparative treatment effectiveness. The inclusion of both an on-treatment cohort and an mITT cohort further enhances the robustness and generalizability of findings by capturing both treatment-adherent patients and the broader target population initiating therapy.
This study also has limitations. As with all observational research, residual confounding cannot be fully excluded despite extensive covariate adjustment and sensitivity analyses. The analysis was limited to a 6-month follow-up period, which may not capture the full magnitude or durability of treatment effects, as clinical trial data suggest that weight reduction typically continues beyond 6 months and often does not plateau until approximately 36 weeks or later, even at lower doses [24]. Dose exposure was inferred from dispensing records, which may not reflect actual patient use. Additionally, missingness in key clinical variables—such as lab values and follow-up weights—may have introduced selection bias, as patients included in the analyses may differ systematically from those without complete data. Although the study used complete case analysis and prespecified outcome windows, the possibility of differential data availability across treatment groups remains a concern. Moreover, in contrast to SURMOUNT-5, the study did not capture waist circumference change and therefore cannot provide insights on the impact of these treatments to clinical measures of excess visceral adiposity, which translate to estimated cardiometabolic risk [7].
In summary, this real-world comparative effectiveness study found that adults without diabetes initiating tirzepatide for obesity management achieved greater weight reduction and improvements in select cardiometabolic risk parameters at 6 months than those initiating semaglutide. Notably, this difference in effectiveness was observed even though fewer tirzepatide-treated patients reached higher available doses compared to semaglutide-treated patients. These findings support and extend the evidence from clinical trials, demonstrating that the superior weight reduction efficacy of tirzepatide is evident in routine clinical practice. As the use of obesity medications expands, the real-world data presented here can inform clinical decision making, payer decisions, and future research aimed at optimizing long-term outcomes in clinical practice.
Supplementary Information
Below is the link to the electronic supplementary material.
Acknowledgements
The authors would like to thank Jennifer Winnie and Vinay Mehta – employees of Eli Lilly and Company for facilitating data acquisition for this study. The authors are also grateful to Chia Lun-Liu, Ryan Simpson, Jack Pfefferkorn, Zoey Kang, and Tayler Li – employees of Analysis Group, Inc. for their support in conducting data analyses.
Authors’ contributions
CWR, HK, GKD, AB, IL, ND, UD, and NK conceptualized and designed the study. HK, ND, UD, NK, and AZ supported data acquisition. AB, ZK, IL, and AZ had access to the raw data and performed analysis as well as verification. CWR, GKD, and JD provided clinical input. All authors had full access to all the data in the study and contributed to interpreting the study findings, preparing the manuscript, reviewed, and approved the manuscript. All authors had final responsibility for the decision to submit the manuscript for publication.
Funding
Eli Lilly and Company.
Declarations
Conflict of interest
ND, UD, and NK are employees of Analysis Group, Inc., a consulting firm that received funding for this research from Eli Lilly and Company. AZ was, at the time of the study, an employee of Analysis Group, Inc., a consulting firm that received funding for this research from Eli Lilly and Company. GKD, AB, IL, JD, and ZK are employees of Eli Lilly and Company and hold stock or stock options in Eli Lilly and Company. HK was an employee of Eli Lilly and Company at the time of the study. CWR reports payments to the institution from the Irish Research Council, Health Research Board, Science Foundation Ireland, and Anabio; consulting fees from NovoNordisk, Eli Lilly, Johnson&Johnson, Boehringer Ingelheim, GI Dynamics, Herbalife, Altimmune, Irish Life Health, Amgen, Arrowhead, Roche, AstraZeneca, Keyron, Gila Pharmaceuticals, Metsera, Nymble, AbbVie, and Olympus; payments for presentations from NovoNordisk, Herbalife, Johnson&Johnson, Eli Lilly, Boehringer Ingelheim, Rhythm Pharmaceuticals, and Currax Pharmaceuticals; support for attending meetings and/or travel from NovoNordisk, Herbalife, Johnson&Johnson, Eli Lilly, and Boehringer Ingelheim; stock/stock options as payment for scientific advisory board contributions from Metsera and Nymble; an unpaid leadership/fiduciary role in the Irish Society for Nutrition and Metabolism; and is a co-owner providing clinical obesity care for My Best Weight and Beyond BMI.
Data sharing
The data that support the findings of this study were licensed from Truveta. Per the Data Use Agreement between Lilly and Truveta, the deposition of data into publicly available repositories is not allowed.
Ethics statement
The study is considered exempt research by the United States Department of Health and Human Services under 45 CFR § 46.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA), specifically, 45 CFR § 164.514.